Industry Mobile Menu Trigger Overview Experience Team Insights Subscribe to insights October 18, 2017 Client Update Life Sciences Securities Litigation Activity in Q3 2017 We previously highlighted the increased activity and some emerging patterns in securities litigation against life sciences... September 8, 2017 Articles & Books Life Sciences Companies Under Attack by Plaintiffs’ Securities Bar In a recent column for the Daily Journal, Davis Polk partners Neal Potischman and Brian Weinstein discuss the flood of sec... July 19, 2017 Client Update Increased Activity and Emerging Patterns in Securities Litigation Against Life Sciences Companies We previously outlined the growing threat of securities class action lawsuits against life sciences companies and the ... January 3, 2017 Client Update White Collar Update: Teva to Pay $519 Million in FCPA Resolution, a Pharmaceutical Industry Record In late December 2016, Teva Pharmaceutical Industries Ltd. (“Teva”), the world’s largest generic pharmaceutical manu... December 6, 2016 Client Update Addressing the Growing Threat of Securities Class Actions in the Life Sciences Sector Life sciences companies are frequent targets of securities litigation. Often, when a company discloses bad news about a de... June 29, 2015 Client Update Third Circuit Holds Non-Cash Consideration – Such As “No Authorized Generic” Agreements – Can Constitute Unlawful “Pay For Delay” First appellate court decision applying FTC v. Actavis (S.Ct. 2013). Court finds rule of reason analysis should be applied... August 24, 2009 Client Update Davis Polk Antitrust Update - August 2009 The federal antitrust regulators, the Federal Trade Commission (“FTC”) and the Antitrust Division of the Department of...
October 18, 2017 Client Update Life Sciences Securities Litigation Activity in Q3 2017 We previously highlighted the increased activity and some emerging patterns in securities litigation against life sciences...
September 8, 2017 Articles & Books Life Sciences Companies Under Attack by Plaintiffs’ Securities Bar In a recent column for the Daily Journal, Davis Polk partners Neal Potischman and Brian Weinstein discuss the flood of sec...
July 19, 2017 Client Update Increased Activity and Emerging Patterns in Securities Litigation Against Life Sciences Companies We previously outlined the growing threat of securities class action lawsuits against life sciences companies and the ...
January 3, 2017 Client Update White Collar Update: Teva to Pay $519 Million in FCPA Resolution, a Pharmaceutical Industry Record In late December 2016, Teva Pharmaceutical Industries Ltd. (“Teva”), the world’s largest generic pharmaceutical manu...
December 6, 2016 Client Update Addressing the Growing Threat of Securities Class Actions in the Life Sciences Sector Life sciences companies are frequent targets of securities litigation. Often, when a company discloses bad news about a de...
June 29, 2015 Client Update Third Circuit Holds Non-Cash Consideration – Such As “No Authorized Generic” Agreements – Can Constitute Unlawful “Pay For Delay” First appellate court decision applying FTC v. Actavis (S.Ct. 2013). Court finds rule of reason analysis should be applied...
August 24, 2009 Client Update Davis Polk Antitrust Update - August 2009 The federal antitrust regulators, the Federal Trade Commission (“FTC”) and the Antitrust Division of the Department of...